All stock lists
Valion Bio, Inc. (NASDAQ:VBIO)
US · Delayed Price · Currency is USD
Healthcare · Biotechnology
0.80-0.14 (-14.87%)
Insider Score
––Not scored
VBIO Insider Score
Insiders here have filed 2 Form 4s in the last 90 days, but all of them are share awards, grants or other non-market transactions. Those are compensation, not a decision to buy, so they are not scored.
VBIO Income Statement
| Fiscal Period | Q2 2026 | Q1 2026 | Q4 2025 | Q3 2025 | Q2 2025 | Q1 2025 |
|---|---|---|---|---|---|---|
| Period Ending | Jun 30, 2026 | Mar 31, 2026 | Dec 31, 2025 | Sep 30, 2025 | Jun 30, 2025 | Mar 31, 2025 |
| Revenue | 0.00 | 0.00 | -302.00 K | 146.00 K | 86.00 K | 0.00 |
| Revenue Growth (YoY) | -100.00 % | — | -267.78 % | 15.87 % | -38.57 % | -100.00 % |
| Cost of Revenue | 358.00 K | 0.00 | 0.00 | 291.00 K | 32.00 K | 1.00 K |
| Gross Profit | -358.00 K | 0.00 | -302.00 K | -145.00 K | 54.00 K | -1.00 K |
| SG&A Expense | 3.72 M | 3.78 M | 733.00 K | 1.48 M | 1.33 M | 1.04 M |
| R&D Expense | 2.70 M | 1.85 M | 1.28 M | 858.00 K | 655.00 K | 335.00 K |
| Operating Expenses | 6.42 M | 5.63 M | 1.67 M | 2.34 M | 1.99 M | 1.38 M |
| Operating Income | -6.42 M | -5.63 M | -1.98 M | -2.48 M | -1.93 M | -1.38 M |
| Pretax Income | -7.06 M | -6.22 M | -1.96 M | -2.60 M | -1.93 M | -1.37 M |
| Tax Provision | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Net Income | -7.10 M | -6.20 M | -2.85 M | -2.60 M | -1.93 M | -1.50 M |
| EPS (Basic) | -54.25 | -55.75 | 0.00 | -1.97 | -2.19 | -65.95 |
| EPS (Diluted) | -54.25 | -55.75 | 0.00 | -1.97 | -2.19 | -65.95 |
| Shares Outstanding | 135.20 K | 115.35 K | 0.00 | 1.32 M | 881.29 K | 22.77 K |
Quarterly figures; YoY compares the same fiscal quarter a year earlier. Source: public market data.
Disclaimer — Informational only — not investment advice. Insider transaction data is sourced from SEC Form 4 filings; market data from public feeds and may be delayed. The Insider Score is a proprietary score for research purposes and does not predict future performance. Always do your own research.